Hideaki Ito
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hideaki Ito has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
Osamu Yokoyama
Departments ofDepartment of UrologyFaculty of Medical SciencesUniversity of FukuiEiheiji Japan
9 shared publicationsMinekatsu Taga
Department of Urology, Faculty of Medical Science, University of Fukui, Fukui, Japan
6 shared publicationsKatsuki Tsuchiyama
Department of Urology, Faculty of Medical Science, University of Fukui, Fukui, Japan
4 shared publicationsHideki Oe
Departments ofDepartment of UrologyFaculty of Medical SciencesUniversity of FukuiEiheiji Japan
3 shared publicationsHironobu Akino
Department of Urology, Faculty of Medical Sciences, and †Biomedical Imaging Research Center, University of Fukui, Fukui
3 shared publications- Nobuyuki Oyama
Department of Urology, University of Fukui, Fukui, Japan
3 shared publications
Latest Publications
- 18 January 2023
- Published by Elsevier in Photodiagnosis and Photodynamic Therapy
- Vol. 41, 103294
Risks and benefits of transurethral resection of the bladder tumor using photodynamic diagnosis with oral 5-aminolevulinic acid hydrochloride according to age and history of recurrence in patients with non-muscle invasive bladder cancer
- 18 January 2023
- Published by Elsevier in Photodiagnosis and Photodynamic Therapy
- Vol. 41, 103294
Risks and benefits of transurethral resection of the bladder tumor using photodynamic diagnosis with oral 5-aminolevulinic acid hydrochloride according to age and history of recurrence in patients with non-muscle invasive bladder cancer
- Open Access
- 8 July 2022
- Published by Elsevier in Continence
- Vol. 2, 100420
446 THE EFFECT OF THE MEDICATIONS BY ALPHA-1 BLOCKERS AND 5 ALPHA REDUCTASE INHIBITORS FOR CHRONIC PROSTATIC INFLAMMATION.
- 8 July 2022
- Published by Elsevier in Continence
- Vol. 2, 100420
Open Access446 THE EFFECT OF THE MEDICATIONS BY ALPHA-1 BLOCKERS AND 5 ALPHA REDUCTASE INHIBITORS FOR CHRONIC PROSTATIC INFLAMMATION.
- 24 July 2020
- Published by Wiley in International Journal of Urology
- Vol. 27 (10) , 874-881
Duration of smoking cessation is negatively associated with the magnitude of chronic prostatic inflammation and storage dysfunction in patients with benign prostatic hyperplasia
Objectives To evaluate the impact of smoking and the benefit of smoking cessation on lower urinary tract function and prostatic inflammation in patients with benign prostatic hyperplasia. Methods The medical records of 118 benign prostatic hyperplasia patients who underwent transurethral prostatic surgery between 2006 and 2016 were analyzed. Their smoking history was confirmed. The relationship between smoking and main clinical parameters, International Prostate Symptom Scores, uroflowmetry, pressure flow study, magnitude of prostatic inflammation and the level of serum C‐reactive protein was investigated. Furthermore, the relationships between smoking cessation and these clinical parameters were assessed. Results The International Prostate Symptom Scores for straining among the non‐smokers were significantly lower than those of the smokers (1.71 vs 2.60, P = 0.029). In the pressure flow study, there were negative correlations between the duration of smoking and strong desire to void (correlation coefficient −0.314, P = 0.013), urgency (correlation coefficient −0.349, P = 0.008) and bladder volume at initial detrusor overactivity (correlation coefficient −0.417, P = 0.021). The duration of smoking cessation was negatively correlated with the magnitude of chronic prostatic inflammation (correlation coefficient −0.253, P = 0.027). In the pressure flow study, the duration of smoking cessation was positively correlated with urgency (correlation coefficient 0.286, P = 0.030) and maximum cystometric capacity (correlation coefficient 0.241, P = 0.050). Conclusions Smoking could be a risk factor for the exacerbation of storage dysfunction in benign prostatic hyperplasia patients. Smoking cessation is effective in improving chronic prostatic inflammation and storage dysfunction.
- 24 July 2020
- Published by Wiley in International Journal of Urology
- Vol. 27 (10) , 874-881
Duration of smoking cessation is negatively associated with the magnitude of chronic prostatic inflammation and storage dysfunction in patients with benign prostatic hyperplasia
Objectives To evaluate the impact of smoking and the benefit of smoking cessation on lower urinary tract function and prostatic inflammation in patients with benign prostatic hyperplasia. Methods The medical records of 118 benign prostatic hyperplasia patients who underwent transurethral prostatic surgery between 2006 and 2016 were analyzed. Their smoking history was confirmed. The relationship between smoking and main clinical parameters, International Prostate Symptom Scores, uroflowmetry, pressure flow study, magnitude of prostatic inflammation and the level of serum C‐reactive protein was investigated. Furthermore, the relationships between smoking cessation and these clinical parameters were assessed. Results The International Prostate Symptom Scores for straining among the non‐smokers were significantly lower than those of the smokers (1.71 vs 2.60, P = 0.029). In the pressure flow study, there were negative correlations between the duration of smoking and strong desire to void (correlation coefficient −0.314, P = 0.013), urgency (correlation coefficient −0.349, P = 0.008) and bladder volume at initial detrusor overactivity (correlation coefficient −0.417, P = 0.021). The duration of smoking cessation was negatively correlated with the magnitude of chronic prostatic inflammation (correlation coefficient −0.253, P = 0.027). In the pressure flow study, the duration of smoking cessation was positively correlated with urgency (correlation coefficient 0.286, P = 0.030) and maximum cystometric capacity (correlation coefficient 0.241, P = 0.050). Conclusions Smoking could be a risk factor for the exacerbation of storage dysfunction in benign prostatic hyperplasia patients. Smoking cessation is effective in improving chronic prostatic inflammation and storage dysfunction.
- Open Access
- 1 November 2019
- Published by Elsevier in Urology Case Reports
- Vol. 27, 100996
Neurogenic bladder associated with xeroderma pigmentosum type A: A case report and literature review
- 1 November 2019
- Published by Elsevier in Urology Case Reports
- Vol. 27, 100996
Open AccessNeurogenic bladder associated with xeroderma pigmentosum type A: A case report and literature review
- 30 September 2019
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 39 (10) , 5417-5425
Low-dose Docetaxel Enhanced the Anticancer Effect of Temsirolimus by Overcoming Autophagy in Prostate Cancer Cells
Background/Aim: Chemotherapy with docetaxel (DTX) is used for castration-resistant prostate cancer (CRPC), but it is inadequate. Materials and Methods: We evaluated the effect of the combination treatment DTX and the mTOR inhibitor temsirolimus (TEM) in the PC3 prostate cancer cell line, by focusing on the induction of autophagy and apoptosis. Results: TEM induced autophagy but not apoptosis even at a high dose, whereas DTX induced apoptosis. The combination of low-dose DTX and TEM caused a 34% suppression in cell proliferation compared to monotherapy with a higher dose of DTX. The induction of apoptosis was increased by their combination. The combination with DTX overcame the induction of autophagy by TEM. The combination treatment suppressed tumor growth 72% less than the control group after 14 days of treatment in vivo. Conclusion: The combination of TEM and DTX induced apoptosis by overcoming autophagy and enhanced the anticancer effect compared to monotherapy.
- 30 September 2019
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 39 (10) , 5417-5425
Low-dose Docetaxel Enhanced the Anticancer Effect of Temsirolimus by Overcoming Autophagy in Prostate Cancer Cells
Background/Aim: Chemotherapy with docetaxel (DTX) is used for castration-resistant prostate cancer (CRPC), but it is inadequate. Materials and Methods: We evaluated the effect of the combination treatment DTX and the mTOR inhibitor temsirolimus (TEM) in the PC3 prostate cancer cell line, by focusing on the induction of autophagy and apoptosis. Results: TEM induced autophagy but not apoptosis even at a high dose, whereas DTX induced apoptosis. The combination of low-dose DTX and TEM caused a 34% suppression in cell proliferation compared to monotherapy with a higher dose of DTX. The induction of apoptosis was increased by their combination. The combination with DTX overcame the induction of autophagy by TEM. The combination treatment suppressed tumor growth 72% less than the control group after 14 days of treatment in vivo. Conclusion: The combination of TEM and DTX induced apoptosis by overcoming autophagy and enhanced the anticancer effect compared to monotherapy.
- Open Access
- 1 September 2019
- Published by Elsevier in Urology Case Reports
- Vol. 26, 100958
Advanced bladder cancer with malignant psoas syndrome: A case report with a focus on physical findings and complications
- 1 September 2019
- Published by Elsevier in Urology Case Reports
- Vol. 26, 100958
Open AccessAdvanced bladder cancer with malignant psoas syndrome: A case report with a focus on physical findings and complications
- Open Access
- 23 July 2019
- Published by Wiley in Neurourology and Urodynamics
- Vol. 38 (8) , 2250-2254
Low and high body mass index values are associated with female nocturia
Aims: We evaluated the relationship between body mass index (BMI), including low BMI, and nocturia in Japanese women.Methods: We collected data on 18 952 women who participated in a multiphasic health screening in Fukui, Japan, in 2006. The participants were asked to report any current or previous disease. Self‐reported current body weight and height were used to calculate the BMI. We analyzed the relationship between nocturia, as assessed by a questionnaire, and other variables including age, BMI, and comorbidities.Results: The participants’ mean age was 60.6 years. Overall, the prevalence of nocturia (two or more voids/night) was 4.3% and increased in an age‐dependent manner. BMI did not affect nocturia in the young participants. The prevalence of nocturia was higher in the high‐BMI women (>25.0 kg/m 2) in their fifth and sixth decades, but the prevalence was higher in the low‐BMI (2) in the women more than 80‐years old. A multivariate analysis revealed a significant association between nocturia and the following: age, BMI, sleep disturbance, arteriosclerosis, cerebrovascular disease, chronic pulmonary disease, diabetes mellitus, and hypertension. Not only high BMI (which is already reported as a risk of nocturia) but also low BMI was a factor related to nocturia.Conclusion: Our findings indicate that in addition to obesity, low BMI is a factor of nocturia in women.
- 23 July 2019
- Published by Wiley in Neurourology and Urodynamics
- Vol. 38 (8) , 2250-2254
Open AccessLow and high body mass index values are associated with female nocturia
Aims: We evaluated the relationship between body mass index (BMI), including low BMI, and nocturia in Japanese women.Methods: We collected data on 18 952 women who participated in a multiphasic health screening in Fukui, Japan, in 2006. The participants were asked to report any current or previous disease. Self‐reported current body weight and height were used to calculate the BMI. We analyzed the relationship between nocturia, as assessed by a questionnaire, and other variables including age, BMI, and comorbidities.Results: The participants’ mean age was 60.6 years. Overall, the prevalence of nocturia (two or more voids/night) was 4.3% and increased in an age‐dependent manner. BMI did not affect nocturia in the young participants. The prevalence of nocturia was higher in the high‐BMI women (>25.0 kg/m 2) in their fifth and sixth decades, but the prevalence was higher in the low‐BMI (2) in the women more than 80‐years old. A multivariate analysis revealed a significant association between nocturia and the following: age, BMI, sleep disturbance, arteriosclerosis, cerebrovascular disease, chronic pulmonary disease, diabetes mellitus, and hypertension. Not only high BMI (which is already reported as a risk of nocturia) but also low BMI was a factor related to nocturia.Conclusion: Our findings indicate that in addition to obesity, low BMI is a factor of nocturia in women.
- 18 June 2019
- Published by Springer Nature in International Cancer Conference Journal
- Vol. 8 (4) , 170-174
Remarkable effect of presurgical nivolumab on originally inoperable papillary renal cell carcinoma with tumor thrombus in inferior vena cava
For the long-term survival of a patient with renal cell carcinoma and a vena cava tumor thrombus, total resection is desired: inoperable patients are sometimes treated with drugs. The effect of the presurgical use of nivolumab, an anti-programmed cell death 1 (PD-1) antibody drug, has been described. Our patient had inoperable renal cancer with an inferior vena cava tumor thrombus. We were able to downsize the tumor to operable size by administrating nivolumab. The patient underwent a nephrectomy and thrombectomy safely. Pathological findings revealed papillary renal cell carcinoma type 2. No viable cells were identified in the removed thrombus. Anti-programmed cell death ligand 1 was expressed on the cell membrane in approximately 20% of the tumor cells, and PD-1 positive tumor-ifiltrating immune cells had infiltrated particularly at the edge of the tumor. This case indicates the positive effect of the presurgical use of nivolumab for advanced papillary renal cell carcinoma.
- 18 June 2019
- Published by Springer Nature in International Cancer Conference Journal
- Vol. 8 (4) , 170-174
Remarkable effect of presurgical nivolumab on originally inoperable papillary renal cell carcinoma with tumor thrombus in inferior vena cava
For the long-term survival of a patient with renal cell carcinoma and a vena cava tumor thrombus, total resection is desired: inoperable patients are sometimes treated with drugs. The effect of the presurgical use of nivolumab, an anti-programmed cell death 1 (PD-1) antibody drug, has been described. Our patient had inoperable renal cancer with an inferior vena cava tumor thrombus. We were able to downsize the tumor to operable size by administrating nivolumab. The patient underwent a nephrectomy and thrombectomy safely. Pathological findings revealed papillary renal cell carcinoma type 2. No viable cells were identified in the removed thrombus. Anti-programmed cell death ligand 1 was expressed on the cell membrane in approximately 20% of the tumor cells, and PD-1 positive tumor-ifiltrating immune cells had infiltrated particularly at the edge of the tumor. This case indicates the positive effect of the presurgical use of nivolumab for advanced papillary renal cell carcinoma.
- 4 June 2019
- Published by Wiley in Neurourology and Urodynamics
- Vol. 38 (6) , 1728-1736
Serum C‐reactive protein level is not associated with prostatic inflammation but with overactive detrusor in patients with benign prostatic hyperplasia
Aim: Chronic prostatic inflammation is a critical factor that exacerbates lower urinary tract symptoms (LUTS). The serum C‐reactive protein (CRP) level is one of the most common markers with which to assess the degree of inflammation, and it has been reported to be related to the severity of LUTS. However, it is not clear whether the CRP level is linked to the magnitude of prostatic inflammation. We evaluated the relationship between the serum CRP level and the magnitude of prostatic inflammation and assessed the influence of CRP on the severity of LUTS.Methods: We evaluated the tissue specimens of 121 benign prostatic hyperplasia (BPH) patients who underwent surgery for BPH and preoperative measurement of the serum CRP level. We quantified the magnitude of prostatic inflammation histologically by determining the number of high endothelial venule (HEV)‐like vessels and assessed the relationship between the serum CRP level and the HEV‐like vessels. We divided the patients into two groups based on the median serum CRP level and compared the clinical parameters of the two groups.Results: The serum CRP level was correlated with the overactive bladder symptom score, whereas it was not correlated with the number of HEV‐like vessels. In filling cystometry and pressure‐flow study, the proportion of patients with detrusor overactivity in the higher‐CRP group was higher than that in the lower‐CRP group.Conclusions: Our present study showed that the serum CRP level was significantly associated with storage dysfunction; in contrast, it was not a surrogate marker of prostatic inflammation.
- 4 June 2019
- Published by Wiley in Neurourology and Urodynamics
- Vol. 38 (6) , 1728-1736
Serum C‐reactive protein level is not associated with prostatic inflammation but with overactive detrusor in patients with benign prostatic hyperplasia
Aim: Chronic prostatic inflammation is a critical factor that exacerbates lower urinary tract symptoms (LUTS). The serum C‐reactive protein (CRP) level is one of the most common markers with which to assess the degree of inflammation, and it has been reported to be related to the severity of LUTS. However, it is not clear whether the CRP level is linked to the magnitude of prostatic inflammation. We evaluated the relationship between the serum CRP level and the magnitude of prostatic inflammation and assessed the influence of CRP on the severity of LUTS.Methods: We evaluated the tissue specimens of 121 benign prostatic hyperplasia (BPH) patients who underwent surgery for BPH and preoperative measurement of the serum CRP level. We quantified the magnitude of prostatic inflammation histologically by determining the number of high endothelial venule (HEV)‐like vessels and assessed the relationship between the serum CRP level and the HEV‐like vessels. We divided the patients into two groups based on the median serum CRP level and compared the clinical parameters of the two groups.Results: The serum CRP level was correlated with the overactive bladder symptom score, whereas it was not correlated with the number of HEV‐like vessels. In filling cystometry and pressure‐flow study, the proportion of patients with detrusor overactivity in the higher‐CRP group was higher than that in the lower‐CRP group.Conclusions: Our present study showed that the serum CRP level was significantly associated with storage dysfunction; in contrast, it was not a surrogate marker of prostatic inflammation.